Armada III to Take Cannabinoid Drugmaker Brains Public at $750M Pre-Money Valuation
AACI is trading near its 52-week low of $9.74 (3.6% above the low).
Summary
Armada III signed a definitive business combination agreement with Brains Bioceutical, a Vancouver-based cannabinoid pharmaceutical company, valuing Brains at roughly $750 million pre-money with existing shareholders rolling 100% of their equity. The merger agreement sets a $10.20 per-share reference value, 14,705,882 earnout shares releasing at $12.50 and $15.00 targets, and a June 30, 2027 termination date. The combined company is expected to list on Nasdaq as Brains Therapeutics Corp. under the ticker BAPI, with closing targeted for Q2 2027. This is the SPAC's first announced target since its February 2026 IPO, and it comes against the 18-month clock disclosed in the August 10-Q, which reported $251.6M held in trust. Brains brings EU-GMP API manufacturing in Kent, England, commercial supply relationships, and a pipeline including an extended-release glaucoma program and an option on an NIH-funded Phase 3 opioid use disorder program. The deal still needs Armada and Brains shareholder votes, an effective F-4 registration statement, Nasdaq listing approval and regulatory clearances, and heavy redemptions could shrink the cash the combined company actually receives. Watch for the 8-K with the merger agreement and investor presentation, then the F-4 filing.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The merger agreement sets a $10.20 per-share reference value, 14,705,882 earnout shares releasing at $12.50 and $15.00 targets, and a June 30, 2027 termination date.
At the time of this announcement, AACI was trading at $10.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $343.4M. The 52-week trading range was $9.74 to $10.10. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.